Biomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel Disease
The use of biological drugs has improved outcomes in pediatric inflammatory bowel disease (IBD). Prediction of the response to biological drugs would be extremely useful in IBD, and even more so in children, who are still growing physically and psychologically. Specific clinical, biochemical, and ge...
Enregistré dans:
Auteurs principaux: | Sara Salvador-Martín, Alejandra Melgarejo-Ortuño, Luis A. López-Fernández |
---|---|
Format: | article |
Langue: | EN |
Publié: |
MDPI AG
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/b275a7c3d7d14dff9e7bd172375fb3fe |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Infliximab Efficacy May Be Linked to Full TNF-α Blockade in Peripheral Compartment—A Double Central-Peripheral Target-Mediated Drug Disposition (TMDD) Model
par: David Ternant, et autres
Publié: (2021) -
Metabolomics Insights into Inflammatory Bowel Disease: A Comprehensive Review
par: Laila Aldars-García, et autres
Publié: (2021) -
Relationship between IGF-1 and body weight in inflammatory bowel diseases: Cellular and molecular mechanisms involved
par: Luis G. Guijarro, et autres
Publié: (2021) -
A Practical Guide to Therapeutic Drug Monitoring of Biologic Medications for Inflammatory Bowel Disease
par: Byron P. Vaughn
Publié: (2021) -
Combined Use of Fecal Biomarkers in Inflammatory Bowel Diseases: Oncostatin M and Calprotectin
par: Cao Y, et autres
Publié: (2021)